Self-Study Modules on Tuberculosis

Module 3

Targeted Testing and the Diagnosis of Latent Tuberculosis Infection and Tuberculosis Disease
Targeted Testing and the Diagnosis of Latent Tuberculosis Infection and Tuberculosis Disease

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
Division of Tuberculosis Elimination

Atlanta, Georgia
2016
Contents

Background ......................................................... 1
Objectives ......................................................... 1
New Terms ......................................................... 2
Targeted Testing .................................................. 6
Diagnosis of LTBI ................................................ 8
Diagnosis of TB Disease ......................................... 39
TB Genotyping ................................................... 69
Additional Resources ........................................... 71
Answers to Study Questions ................................. 73
Case Study Answers ............................................. 81
Background

In this module, you will learn about targeted testing and the diagnosis of latent tuberculosis (TB) infection (LTBI) and TB disease. Targeted testing is a TB control strategy that is used to identify people who have LTBI and are at high risk for developing TB disease and would benefit from treatment. LTBI is diagnosed with the Mantoux tuberculin skin test (TST) or an interferon-gamma release assay (IGRA), such as the QuantiFERON®-TB Gold In-Tube test (QFT-GIT) or the T-SPOT® TB test (T-Spot).

It is important to medically evaluate people who have symptoms of TB disease; if they are found to have TB disease, they need treatment to be cured and to help stop the transmission of TB to others. For this reason, the diagnosis of TB disease is crucial to controlling the spread of TB in homes and communities. In most cases, TB disease is diagnosed with certain laboratory tests. For patients who may have pulmonary TB disease, a chest x-ray is also useful for diagnosis.

Note: The Self-Study Modules on Tuberculosis are a series of educational modules designed to provide information about TB in a self-study format. The target audiences include outreach workers, nurses, physicians, administrators, health educators, and students from a variety of settings. The Modules should not be used as a substitute for guidelines and should not be used for patient care decisions.

Objectives

After working through this module, you will be able to

1. Identify high-risk groups for targeted testing.
2. Describe how to place, read, and interpret a Mantoux tuberculin skin test.
3. Describe how to interpret an interferon-gamma release assay.
4. Discuss considerations for using either the Mantoux tuberculin skin test or an interferon-gamma release assay for diagnosing latent tuberculosis infection.
5. Describe the components of a medical evaluation for diagnosing TB disease.
**New Terms**

New terms introduced in this module are included below. These terms appear in **bold** in the module text.

- **acid-fast bacilli (AFB)**—mycobacteria that when stained, retain color even after they have been washed in an acid solution; may be detected under a microscope in a stained smear
- **anergy**—the inability to react to a skin test because of a weakened immune system, often caused by HIV infection or severe illness
- **antigen**—protein substances that can produce an immune response (such as CFP-10, ESAT-6, or those in PPD)
- **bacteriologic examination**—tests done in a mycobacteriology laboratory to aid diagnosis of TB disease; includes examining a specimen under a microscope, culturing the specimen, and testing for drug susceptibility
- **baseline skin test**—a tuberculin skin test (TST) given to employees or residents in certain facilities when they start their job or enter the facility (see TB testing program and two-step testing)
- **BCG**—bacille Calmette-Guérin (BCG), a vaccine for TB disease that is used in many countries but rarely used in the United States; may cause a false-positive reaction to the TST but does not affect interferon-gamma release assay (IGRA) results
- **boosted reaction**—a positive reaction to a TST, due to a boosted immune response from a skin test given up to a year earlier; occurs in people who were infected a long time ago and whose ability to react to tuberculin has lessened. Two-step testing is used in TB testing programs to tell the difference between boosted reactions and reactions caused by recent infection (see booster phenomenon and two-step testing).
- **booster phenomenon**—a phenomenon in which people (especially older adults) who are skin tested many years after becoming infected with *M. tuberculosis* may have a negative reaction to an initial TST, followed by a positive reaction to a TST given up to a year later; this happens because the first
TST boosts the immune response. Two-step testing is used in TB testing programs to tell the difference between boosted reactions and reactions caused by recent infection (see two-step testing).

**bronchoscopy**—a procedure used to obtain pulmonary secretions or lung tissue with an instrument called a bronchoscope; used only when patients cannot cough up sputum on their own and an induced specimen cannot be obtained

**cavity**—a hollow space within the lung, visible on a chest x-ray, that may contain many tubercle bacilli; often occurs in people with severe pulmonary TB disease

**CFP-10**—one of the antigens used in IGRAs that is found in *M. tuberculosis* strains but not in BCG vaccine strains

**clinician**—a physician, physician’s assistant, or nurse

**colonies**—groups of mycobacteria that have grown on solid media

**control**—a standard of comparison for checking or verifying the results of an experiment

**culture**—to grow organisms in media (substances containing nutrients) so that they or the product of this process can be identified; a positive culture for *M. tuberculosis* contains tubercle bacilli, whereas a negative culture contains no detectable tubercle bacilli

**drug susceptibility pattern**—the list of antituberculosis drugs to which a strain of tubercle bacilli is susceptible and to which it is resistant

**erythema**—redness around the site of the injection when a TST is done; erythema is not measured as part of the reaction size because redness does not indicate that a person has TB infection

**ESAT-6**—one of the antigens used in IGRAs that is found in *M. tuberculosis* strains but not in BCG vaccine strains

**exposure to TB**—time spent with or near someone who has infectious TB disease

**false-negative reaction**—a negative reaction to the TST or IGRA in a person who has TB infection

**false-positive reaction**—a positive reaction to the TST or IGRA in a person who does not have TB infection

**gastric washing**—a procedure done by inserting a tube through the patient’s nose and passing it into the stomach; may be useful for obtaining a specimen for culture from children, who produce little or no sputum when they cough

**GeneXpert**—a semi-automated molecular diagnostic system. See Xpert MTB/RIF assay.

**genotype**—distinct genetic pattern of an organism

**genotyping**—a laboratory-based method that can determine the genetic pattern of the strain of *M. tuberculosis* that caused TB disease in a person

**induced sputum**—sputum that is obtained by having the patient inhale a saline (salt water) mist, causing the patient to cough deeply; this procedure is used to help patients cough up sputum if they cannot do so on their own

**induration**—swelling that can be felt around the site of injection after a TST is done; the reaction size is the diameter of the swollen area, measured across the forearm

**infiltrate**—a collection of fluid and cells in the tissues of the lung; visible on a chest x-ray in people with pulmonary TB disease
**interferon-gamma (IFN-γ)**—protein that is normally produced by the body in response to infection. IGRA interpretations are based on the amount of IFN-γ that is released or on the number of cells that release IFN-γ.

**interferon-gamma release assay (IGRA)**—a type of blood test that measures a person’s immune reactivity to *M. tuberculosis*. In the United States, the QuantiFERON®-TB Gold In-Tube (QFT-GIT) and the T-SPOT®.TB test (T-Spot) are currently available IGRA.

**isolate**—a group of organisms isolated or separated from a specimen; in an *M. tuberculosis* isolate, the organisms have been grown in culture and identified as *M. tuberculosis*

**malaise**—a feeling of general discomfort or illness

**Mantoux tuberculin skin test (TST)**—a method of testing for TB infection; a needle and syringe are used to inject 0.1 ml (5 tuberculin units) of purified protein derivative (PPD) tuberculin solution between the layers of the skin (intradermally), usually on the forearm; the reaction to this test, usually a small swollen area (induration), is measured 48 to 72 hours after the injection and is interpreted as positive or negative depending on the size of the reaction and the patient’s risk factors for TB; the routine methodology for tuberculin skin testing worldwide; supersedes all older methods

**media**—substances containing special nutrients and used for growing cultures of bacteria found in specimens

**medical history**—the part of a patient’s life history that is important for diagnosing and treating TB infection or disease, including history of exposure, symptoms, previous diagnosis of TB infection or disease, and risk factors for TB disease

**mycobacteriology laboratory**—a laboratory that deals specifically with *M. tuberculosis* and other mycobacteria

**nucleic acid amplification (NAA)**—a technique that amplifies (copies) DNA and RNA segments. Often used in assays to directly detect microorganisms in sputum specimens.

**polymerase chain reaction (PCR)**—a type of NAA used to make many copies of a segment of DNA

**PPD (purified protein derivative)**—antigens such as the type of tuberculin used in the TST (see antigen)

**QuantiFERON®-TB Gold In-Tube test (QFT-GIT)**—a blood test used to determine TB infection. The QFT-GIT measures the response to simulated TB proteins when they are mixed with a small amount of whole blood

**resistant**—an organism’s ability to grow despite the presence of a particular drug

**skin test conversion**—a change in a skin test reaction from negative to positive between testing intervals

**smear**—a specimen that has been smeared onto a glass slide, stained, washed in an acid solution, and then placed under the microscope for examination; used to detect acid-fast bacilli in a specimen

**sputum**—phlegm from deep in the lungs, collected in a sterile container for processing and examination

**susceptible**—an organism’s ability to be killed by a particular drug

**symptoms of TB disease**—noticeable conditions caused by TB disease. The symptoms of pulmonary TB disease include coughing, pain in the chest when breathing or coughing, and coughing up sputum or blood. The general symptoms of TB disease (pulmonary or
extrapulmonary) include weight loss, fatigue, malaise, fever, and night sweats. The symptoms of extrapulmonary TB disease depend on the part of the body that is affected by the disease.

**targeted testing**—a TB control strategy to identify persons at high risk for latent TB infection and persons at high risk for developing TB disease who would benefit from treatment

**TB7.7**—one of the antigens used in the QFT-GIT

**TB testing program**—a program in which employees and residents of a facility are periodically tested for TB; done to identify people who have TB infection and possibly TB disease and to determine whether TB is being transmitted in the facility

**T-SPOT®.TB Test (T-Spot)**—a blood test used to determine TB infection; the T-Spot measures the number of T cells that secrete IFN-γ upon activation by *M. tuberculosis* antigens

**tuberculin**—a substance made from tubercle bacilli that have been killed by heating; used to determine whether a person has TB infection. Tuberculin is not a vaccine.

**tuberculin skin test (TST)**—a test used to detect TB infection (see Mantoux tuberculin skin test)

**tuberculin unit**—a standard strength of tuberculin used in the United States and Canada; a strength of 5 tuberculin units is used for the Mantoux TST

**two-step testing**—a strategy used in TB testing programs to distinguish a boosted reaction (caused by TB infection that occurred many years ago) from a reaction caused by recent infection. If a person has a negative reaction to an initial skin test, a second test is given 1 to 3 weeks later; a positive reaction to the second test probably represents a boosted reaction, not recent infection. Two-step testing is used in many TB testing programs for skin testing employees when they start their job.

**window period**—the time between a person's last exposure to infectious TB and when a TST or IGRA can reliably detect infection with *M. tuberculosis*

**Xpert MTB/RIF assay**—a nucleic acid amplification (NAA) test that simultaneously identifies *Mycobacterium tuberculosis* complex and rifampin resistance in a sputum sample
Targeted Testing

Targeted testing is the TB control strategy that is used to identify and treat persons who are at high risk for latent TB infection (LTBI) or at high risk for developing TB disease once infected with *M. tuberculosis*. Identifying persons with LTBI is important to the goal of TB elimination because LTBI treatment can prevent these persons from developing TB disease and thereby stop the further spread of TB to others.

Thus, during routine patient evaluations, health care providers should identify persons who are at high risk for TB and test them for LTBI. However, TB testing activities should be done only when there is a plan for follow-up care to evaluate and treat all individuals diagnosed with LTBI or TB disease. Healthcare agencies or other facilities should consult with the local health department before starting a TB testing program to make sure that any person whose test result is positive will have access to follow-up care.

People who are not at high risk for LTBI generally should not be tested. Testing in low-risk populations can take resources away from other important activities. Also, positive test results in low-risk populations are sometimes inaccurate. However, there may be instances in which health care providers are asked to test individuals who are not generally considered as high risk (for example, daycare center workers, teachers, and college students) because of local policies and procedures.

Identifying High-Risk Groups for TB Testing

High-risk groups can be divided into two categories:

- People who are at high risk for exposure to or infection with *M. tuberculosis*
- People who are at high risk for developing TB disease once infected with *M. tuberculosis*

Flexibility should be used in defining high-risk groups for testing. Since the epidemiology of TB can change, the risk of LTBI or TB disease among groups may change over time. Groups that are currently identified as being at low-risk may later be considered high priority. Moreover, because of the differences in populations from one community to another,
definitions of high risk should be made at the local (city, county, or state) level according to local demographics and TB epidemiology.

In general, however, high-risk groups listed in both categories of Table 3.1 should be tested.

### Table 3.1 Groups at High Risk for TB Infection and TB Disease.

<table>
<thead>
<tr>
<th>People at High Risk for Exposure to or Infection with <em>M. tuberculosis</em></th>
<th>People at High Risk for Developing TB Disease after Infection with <em>M. tuberculosis</em></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Contacts</strong> of people known or suspected to have TB disease</td>
<td>People living with HIV</td>
</tr>
<tr>
<td>People who have come to the United States within the last 5 years from areas of the world where TB is common (for example, Asia, Africa, Russia, Eastern Europe, or Latin America)</td>
<td>Children younger than 5 years of age</td>
</tr>
<tr>
<td>People who visit areas with a high prevalence of TB disease, especially if visits are frequent or prolonged</td>
<td>People recently infected with <em>M. tuberculosis</em> (within the past 2 years)</td>
</tr>
<tr>
<td>People who live or work in high-risk congregate settings (for example, nursing homes, homeless shelters, or correctional facilities)</td>
<td>People with a history of untreated or inadequately treated TB disease</td>
</tr>
<tr>
<td>Health care workers who serve patients who are at increased risk for TB disease</td>
<td>Persons who are receiving immunosuppressive therapy such as tumor necrosis factor-alpha (TNF) antagonists, systemic corticosteroids equivalent to/greater than 15 mg of prednisone per day, or immunosuppressive drug therapy following organ transplantation</td>
</tr>
<tr>
<td>Populations defined locally as having an increased incidence of LTBI or TB disease, possibly including medically underserved, low-income populations, or persons who abuse drugs or alcohol</td>
<td>Persons with silicosis, diabetes mellitus, chronic renal failure, leukemia, or cancer of the head, neck, or lung</td>
</tr>
<tr>
<td>Infants, children, and adolescents exposed to adults who are at increased risk for LTBI or TB disease</td>
<td>Persons who have had a gastrectomy or jejunoileal bypass</td>
</tr>
<tr>
<td></td>
<td>Low body weight</td>
</tr>
<tr>
<td></td>
<td>Cigarette smokers and persons who abuse drugs or alcohol</td>
</tr>
<tr>
<td></td>
<td>Populations defined locally as having an increased incidence of disease due to <em>M. tuberculosis</em>, including medically underserved, low-income populations.</td>
</tr>
</tbody>
</table>
Diagnosis of LTBI

Currently, the available methods of testing for *M. tuberculosis* infection are the Mantoux tuberculin skin test (TST) and the interferon-gamma release assays (IGRAs) such as the QuantiFERON®.TB Gold In-Tube (QFT-GIT) test or the T-SPOT®.TB test (T-Spot).

The Mantoux Tuberculin Skin Test (TST)

The TST is used to determine if a person is infected with *M. tuberculosis*. In this test, a substance called tuberculin is injected into the skin. Tuberculin contains antigens used for diagnosing TB infection; it is not a vaccine. An antigen is a protein substance that can produce an immune response. Tuberculin is made from proteins derived from tubercle bacilli that have been killed by heating. In most people who have TB infection, the immune system will recognize the tuberculin because it is similar to the tubercle bacilli that caused infection. This will cause a reaction to the tuberculin at the site of the injection. Tuberculin used for the skin test is also known as purified protein derivative, or PPD.

Administering the TST

The TST is given by using a single dose disposable tuberculin syringe to inject 0.1 ml of 5 tuberculin units of liquid tuberculin between the layers of the skin (intradermally), on the forearm (Figure 3.1). A tuberculin unit is a standard strength of tuberculin. When giving the TST, institutional guidelines for infection control should be followed.

A patient’s forearm should be examined by a trained health care worker 48 to 72 hours after the tuberculin is injected. Health care workers should not ask patients to read their own skin test results. Most people with TB infection will have a positive reaction to the tuberculin. The reaction is an area of induration (swelling that can be felt) around the site of the injection. The diameter of the indurated area is measured in millimeters across the forearm (Figure 3.2); erythema (redness) around the indurated area is not measured, because the presence of erythema does not indicate that a person has TB infection (Figure 3.3).
Module 3—Targeted Testing and the Diagnosis of Latent Tuberculosis Infection and Tuberculosis Disease

Figure 3.1 Administering the Mantoux TST.

Figure 3.2 Only the induration is being measured. This is CORRECT.

Figure 3.3 The erythema is being measured. This is INCORRECT.
Study Question 3.1–3.2

3.1 What is the TST used for?

3.2 How is the TST given?
Study Question 3.3–3.4

3.3 With the TST, when is the patient’s arm examined?

3.4 How is the induration measured?
Interpreting the Reaction

Interpreting a TST reaction depends on the size of the induration and the person’s risk factors for TB (Table 3.2).

An induration of **5 or more millimeters** is considered a positive reaction for the following people:
- People living with HIV
- Recent contacts of people with infectious TB
- People with chest x-ray findings suggestive of previous TB disease
- People with organ transplants
- Other immunosuppressed patients (for example, patients on prolonged therapy with corticosteroids equivalent to/greater than 15mg per day of prednisone or those taking TNF-alpha antagonists)

An induration of **10 or more millimeters** is considered a positive reaction for the following people:
- People who have recently come to the United States (within the last 5 years) from areas of the world where TB is common (for example, Asia, Africa, Russia, Eastern Europe, or Latin America)
- People who abuse drugs
- Mycobacteriology laboratory workers
- People who live or work in high-risk congregate settings (for example, nursing homes, homeless shelters, or correctional facilities)
- People with certain medical conditions that place them at high risk for TB (for example, silicosis, diabetes mellitus, severe kidney disease, certain types of cancer, and certain intestinal conditions)
- Children younger than 5 years of age
- Infants, children, or adolescents exposed to adults in high-risk categories

An induration of **15 or more millimeters** is considered a positive reaction for people with no known risk factors for TB. However, it is important to remember that testing for TB infection should generally be targeted towards high-risk groups, since test results in low-risk groups can be inaccurate.

Most people who have a positive TST reaction will usually have a positive reaction every time they are tested, regardless of whether they receive treatment. This is because the TST detects the immune response to tuberculin, not the presence of tubercle bacilli in the body.
Thus the TST should not be performed on a person who has a documented history of either a positive TST result or treatment for TB disease.

**Interpreting the TST Reaction for Occupational Exposure**

For people who may be exposed to TB on the job (such as health care workers and staff of nursing homes or correctional facilities), the interpretation of the TST reaction as positive or negative depends on

- The employee’s individual risk factors for TB
- The risk of exposure to TB in the person’s job

Therefore, in facilities where TB patients receive care, 10 or more millimeters of induration may be considered a positive reaction for employees with no other risk factors for TB. In facilities where the risk of exposure to TB is very low, 15 or more millimeters of induration may be considered a positive reaction for employees with no other risk factors for TB.

**Table 3.2 Interpreting the TST reaction.**

<table>
<thead>
<tr>
<th>Induration</th>
<th>Positive for</th>
<th>Induration</th>
<th>Positive for</th>
<th>Induration</th>
<th>Positive for</th>
</tr>
</thead>
<tbody>
<tr>
<td>5 or more millimeters</td>
<td>People living with HIV</td>
<td>People who have recently come to the United States (within the last 5 years) from areas of the world where TB is common (for example, Asia, Africa, Russia, Eastern Europe, or Latin America)</td>
<td>People with no known risk factors for TB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10 or more millimeters</td>
<td>Recent contacts of people with infectious TB</td>
<td>People who abuse drugs</td>
<td>Mycobacteriology laboratory workers</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15 or more millimeters</td>
<td>People with chest x-ray findings suggestive of previous TB disease</td>
<td>People who live or work in high-risk congregate settings (for example, nursing homes, homeless shelters, or correctional facilities)</td>
<td>People with certain medical conditions that place them at high risk for TB (for example, silicosis, diabetes mellitus, severe kidney disease, certain types of cancer, and certain intestinal conditions)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>People with organ transplants</td>
<td>People with certain medical conditions that place them at high risk for TB (for example, silicosis, diabetes mellitus, severe kidney disease, certain types of cancer, and certain intestinal conditions)</td>
<td>Children younger than 5 years of age</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Other immunosuppressed patients (for example, patients on prolonged therapy with corticosteroids equivalent to / greater than 15mg per day of prednisone or those taking TNF-alpha antagonists)</td>
<td>Infants, children, and adolescents exposed to adults in high-risk categories</td>
<td>Infants, children, and adolescents exposed to adults in high-risk categories</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
3.5 What two factors determine the interpretation of a skin test reaction as positive or negative? What additional factor is considered for people who may be exposed to TB on the job?

3.6 Name five groups of people for which 5 or more millimeters of induration is considered a positive reaction.

Answers to study questions are on pages 73–80
Study Questions 3.7–3.8

3.7 Name seven groups of people for which 10 or more millimeters of induration is considered a positive reaction.

3.8 For which group of people is 15 or more millimeters of induration considered a positive reaction?
Case Study 3.1

Which of the following patients have a positive TST reaction? Circle the best answer(s).

a) Mr. West, 36 years old, HIV infected, 8 mm of induration

b) Ms. Hernandez, 26 years old, native of Mexico, 7 mm of induration

c) Ms. Jones, 56 years old, has diabetes, 12 mm of induration

d) Mr. Sung, 79 years old, resident of a nursing home, 11 mm of induration

e) Mr. Williams, 21 years old, no known risk factors, 13 mm of induration

f) Ms. Marcos, 42 years old, chest x-ray findings suggestive of previous TB, 6 mm of induration

g) Ms. Rayle, 50 years old, husband has pulmonary TB, 9 mm of induration

Answers to case studies are on pages 81–84
False-Positive Reactions

TST is a valuable tool, but it is not perfect. Several factors may cause people to have a positive reaction even if they do not have TB infection. This is called a **false-positive reaction**.

The causes of false positive reactions may include, but are not limited to, the following:

- Infection with nontuberculous mycobacteria (NTM) (mycobacteria other than *M. tuberculosis*)
- BCG vaccination
- Administration of incorrect antigen
- Incorrect measuring or interpretation of the TST reaction

Infection with NTM can sometimes cause a false positive reaction to the TST. Another cause of a false positive reaction is **BCG (bacille Calmette-Guérin)**; a vaccine for TB disease that is used in many countries but is rarely used in the United States because studies have shown that it is not completely effective. People who have been vaccinated with BCG may have a positive reaction to the TST even if they do not have TB infection. There is no reliable way to distinguish a positive TST reaction caused by BCG vaccination from a reaction caused by true TB infection. Thus, when using the TST, people who have been vaccinated with BCG should always be further evaluated for LTBI or TB disease as if they were not vaccinated with BCG.

A false-positive reaction may also occur if an incorrect antigen is used or when the results are not measured or interpreted properly.
Study Questions 3.9–3.10

3.9  Name four factors that may cause false-positive reactions to the TST.

3.10  Is there a reliable way to distinguish a positive tuberculin reaction caused by vaccination with BCG from a reaction caused by true TB infection?
Case Study 3.2

A 30-year-old man who recently immigrated to the United States from India is given a TST and found to have 14 millimeters of induration. He reports that he was vaccinated with BCG as a child. He also says that his wife was treated for pulmonary TB disease last year.

How should this man’s results be interpreted?

What factors make it more likely that this man’s positive reaction is due to TB infection?
False-Negative Reactions

Some people have a negative reaction to the TST even though they have TB infection. This is called a false-negative reaction. The reasons for these false-negative reactions may include, but are not limited to the following:

- Anergy
- Recent TB infection (within the past 8 to 10 weeks)
- Very young age (younger than 6 months)
- Recent live-virus measles or smallpox vaccination
- Incorrect method of giving the TST
- Incorrect measuring or interpretation of TST reaction

A common cause of false-negative reactions is anergy. **Anergy** is the inability to react to skin tests because of a weakened immune system. HIV infection is an important cause of anergy, but many other conditions, such as cancer, measles or other viral infections, or even a severe case of TB disease, can weaken the immune system and cause anergy.

Another cause of a false-negative reaction is **recent TB infection** (infection within the past 8 to 10 weeks). It can take 2 to 8 weeks after TB infection for the body’s immune system to be able to react to tuberculin and for the infection to be detected by the TST. The time between a person’s last exposure to infectious TB and when a test can reliably detect infection with *M. tuberculosis* is referred to as the **window period**. For this reason, it is recommended that contacts of someone with infectious TB disease who have a negative test result be retested 8 to 10 weeks after the last time they were in contact with the person who has TB disease.

A third cause of false-negative reactions is **very young age**. Because their immune systems are not yet fully developed, children younger than 6 months of age may have a false-negative reaction to the TST.

Vaccination with live viruses may also lead to a false-negative reaction. The Advisory Committee on Immunization Practices recommends that skin testing be done on either the same day as vaccination with live-virus measles vaccine or 4 to 6 weeks after vaccination to prevent possible false-negative reactions. Also, skin testing should not be done until at least 1 month after a smallpox vaccination.

A false-negative reaction may also occur when the TST is given incorrectly or the results are not measured or interpreted properly.
Both false-positive and false-negative reactions to the TST are summarized in Table 3.3.

Any patient with symptoms of TB should be evaluated for TB disease, regardless of his or her skin test reaction. In fact, people with symptoms of TB should be evaluated for TB disease right away, at the same time that the TST is given. TB symptoms and the diagnosis of disease are discussed later in this module.

### Table 3.3 False-positive and false-negative reactions to the TST.

<table>
<thead>
<tr>
<th>Type of Reaction</th>
<th>Possible Cause</th>
<th>People at Risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>False-positive</td>
<td>Nontuberculous mycobacteria (NTM)</td>
<td>People infected with NTM</td>
</tr>
<tr>
<td></td>
<td>BCG vaccination</td>
<td>People vaccinated with BCG</td>
</tr>
<tr>
<td></td>
<td>Administering incorrect antigen</td>
<td>Any person being tested</td>
</tr>
<tr>
<td></td>
<td>Incorrect interpretation of TST result</td>
<td>Any person being tested</td>
</tr>
<tr>
<td>False-negative</td>
<td>Anergy</td>
<td>HIV-infected people, other people with weakened immune systems, severe TB disease, and some viral illness (e.g., measles and chicken pox)</td>
</tr>
<tr>
<td></td>
<td>Recent TB infection</td>
<td>People infected with <em>M. tuberculosis</em> within the past 8 to 10 weeks</td>
</tr>
<tr>
<td></td>
<td>Very young age</td>
<td>Children younger than 6 months of age</td>
</tr>
<tr>
<td></td>
<td>Recent live-virus measles or small pox vaccination</td>
<td>Any person who will receive or has recently received a live-virus vaccination</td>
</tr>
<tr>
<td></td>
<td>Incorrect method of giving TST</td>
<td>Any person being tested</td>
</tr>
<tr>
<td></td>
<td>Incorrect interpretation of TST result</td>
<td>Any person being tested</td>
</tr>
</tbody>
</table>
3.11 Name six factors that can cause false-negative reactions to the TST.

3.12 What is anergy?

Answers to study questions are on pages 73–80
Study Questions 3.13–3.14

3.13 After TB germs have been transmitted to someone, how long does it take before TB infection can be detected by the TST?

3.14 What should be done if a patient has a negative TST result, but has symptoms of TB disease?

Answers to study questions are on pages 73–80
Mr. Bell comes to the TB clinic for a TST. He believes that he has been exposed to TB, and he knows he is at high risk for TB because he is HIV infected. He is given a TST, and his reaction is read 48 hours later as 0 millimeters of induration.

What are three ways to interpret this result?
Interferon-Gamma Release Assays

Interferon-gamma release assays (IGRAs) are blood tests that help diagnose *M. tuberculosis* infection by measuring a person’s immune reactivity to *M. tuberculosis*. White blood cells from most people who are infected with *M. tuberculosis* will release interferon-gamma (IFN-γ) when mixed with antigens derived from *M. tuberculosis*.

Two IGRAs are currently available in the United States:
- QuantiFERON®-TB Gold In-Tube test (QFT-GIT) (Figure 3.4); and
- T-SPOT®.TB test (T-Spot) (Figure 3.5).

The QFT-GIT was approved by the Food and Drug Administration in October 2007 and the T-Spot was approved in 2008. In 2010, the CDC published *Updated Guidelines for Using Interferon Gamma Release Assays to Detect Mycobacterium tuberculosis Infection* (www.cdc.gov/tb).

Conducting an IGRA

To conduct an IGRA, a patient’s blood samples are mixed with antigens and controls. The antigens, testing methods, and interpretation criteria for each of the IGRAs differ (Table 3.4).

Health care workers should be properly trained on how to conduct an IGRA. In general, health care workers should read the instructions from the manufacturer and follow the steps below:
- Confirm arrangements for testing in a qualified laboratory.
- Arrange for delivery of the blood sample to the laboratory in the time the laboratory specifies to ensure testing of samples with viable blood cells.
- Draw a blood sample from the patient according to the test manufacturer’s instructions.
- Schedule a follow-up appointment for the patient to receive test results.
- Based on test results, provide follow-up evaluation and treatment as needed.
Table 3.4 Differences in currently available IGRAs.

<table>
<thead>
<tr>
<th></th>
<th>QFT-GIT</th>
<th>T-Spot</th>
</tr>
</thead>
<tbody>
<tr>
<td>Processing Time</td>
<td>Process whole blood within 16 hours</td>
<td>Process blood cells within 8 to 30 hours</td>
</tr>
<tr>
<td>M. tuberculosis Antigens</td>
<td>ESAT-6, CFP-10, and TB7.7</td>
<td>ESAT-6 and CFP-10</td>
</tr>
<tr>
<td>Measurement</td>
<td>IFN-γ concentration</td>
<td>Number of IFN-γ producing cells (spots)</td>
</tr>
<tr>
<td>Possible Results</td>
<td>Positive, negative, indeterminate</td>
<td>Positive, negative, indeterminate, borderline</td>
</tr>
</tbody>
</table>

How IGRAs Work

Patient blood samples are mixed with antigens (protein substances that can produce an immune response) and incubated. The antigens used, **ESAT-6**, **CFP-10**, and **TB7.7** are found in *M. tuberculosis* strains. If a person has *M. tuberculosis* infection, the blood cells in the sample will recognize the antigens and release IFN-γ in response. IFN-γ is a protein that the body produces in response to infections.

Blood samples are also mixed with control substances. These controls are used for comparison purposes to help verify test results and to determine a person’s background level of IFN-γ.

Interpreting IGRA Results

QFT-GIT results are based on the amount of IFN-γ that is released in response to the *M. tuberculosis* antigens and control substances. T-Spot results are based on the number of IFN-γ producing cells (spots) produced.

Laboratories should report both the qualitative and quantitative test results. Qualitative results are reported as positive, negative, indeterminate, or borderline (Table 3.5). Quantitative results are reported as numerical values. Quantitative results may be useful for clinical decision making in combination with the patient’s risk factors.

To calculate the test results, laboratories use software provided by the manufacturer. The laboratory conducting the analysis of the IGRA will then submit a report of the results back to the health care provider who requested the test.
As with the TST, medical evaluation and additional tests (such as chest x-rays, sputum smears, and culture) are needed to confirm the diagnosis of LTBI or TB disease.

**Table 3.5 Interpretation of IGRA results.**

<table>
<thead>
<tr>
<th>IGRA Result</th>
<th>Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Positive</td>
<td><em>M. tuberculosis</em> infection likely</td>
</tr>
<tr>
<td>Negative</td>
<td><em>M. tuberculosis</em> infection unlikely, but cannot be excluded especially if</td>
</tr>
<tr>
<td></td>
<td>1. Patient has signs and symptoms of TB</td>
</tr>
<tr>
<td></td>
<td>2. Patient has a high risk for developing TB disease once infected with <em>M. tuberculosis</em></td>
</tr>
<tr>
<td>Indeterminate</td>
<td>The test did not provide useful information about the likelihood of <em>M. tuberculosis</em> infection. Repeating an IGRA or performing a TST may be useful.</td>
</tr>
<tr>
<td>Borderline (T-Spot only)</td>
<td>The test did not provide useful information about the likelihood of <em>M. tuberculosis</em> infection. Repeating an IGRA or performing a TST might be useful.</td>
</tr>
</tbody>
</table>

Persons who test positive for TB infection should be evaluated for TB disease and, if disease is ruled out, they should be considered for LTBI treatment.

If the IGRA result is positive, then it is likely that the patient has *M. tuberculosis* infection. There is no reason to follow a positive IGRA result with a TST. However, TB disease should be ruled out by medical evaluation before LTBI is diagnosed.

If the IGRA result is negative, then the patient is unlikely to have *M. tuberculosis* infection and may not require further evaluation unless he or she has signs and symptoms of TB disease. As with the TST, persons who have a negative test result can still have LTBI.

If the IGRA result is indeterminate or borderline, that means that the test did not provide useful information about the likelihood of *M. tuberculosis* infection. Repeating an IGRA or performing a TST may be useful.

Health care workers should consider each IGRA result and its interpretation along with other epidemiologic, historical, physical, and diagnostic findings. Regardless of test results, if a patient has signs and symptoms of TB disease or if they are at high risk for developing TB disease, they should receive further evaluation.
As with the TST, negative IGRA results for contacts to persons with infectious TB should be confirmed with a repeat test 8 to 10 weeks after their last exposure to TB.

**IGRA Recommendations**

An IGRA may be used in place of a TST in all situations in which the TST is recommended. However, there are a few preferences and special considerations when determining which test to use. For example, IGRA are the preferred method of testing for:

- Groups of people who might be less likely to return for TST reading and interpretation (for example, homeless persons or drug users)
- Persons who have received the BCG vaccine

The TST is the preferred method of testing for children younger than 5 years of age.

Routine testing using both TST and IGRA is NOT recommended. However, there are certain situations where results from both tests may be useful:

- When the initial test is **negative** and:
  - The risk for infection, progression to disease, or a poor outcome is high (for example, persons living with HIV or children younger than 5 years of age are exposed to a person with infectious TB).
  - There is clinical suspicion for TB disease (for example, signs, symptoms, or radiographic evidence suggestive of TB disease) and confirmation of *M. tuberculosis* infection is desired.

- When the initial test is **positive** and:
  - Additional evidence of infection is required to encourage the patient’s acceptance and adherence to treatment.
  - The person has a low risk of both infection and progression from infection to TB disease.

In addition, repeating an IGRA or performing a TST might be useful when the initial IGRA result is indeterminate, borderline, or invalid and a reason for testing persists.
Advantages of IGRAs

There are advantages and limitations to using IGRAs. Below are some advantages to using an IGRA compared to using the TST (Table 3.6).

- Requires a single patient visit to conduct the test
- Results can be available within 24 hours
- Does not cause the booster phenomenon which can happen with repeat TSTs (see page 33 of this module for more information on the booster phenomenon)
- Previous BCG vaccination does not cause a false-positive result

An advantage of using an IGRA compared to the TST is that it only requires one patient visit to conduct the test and results can be available within 24 hours. The TST requires two visits by the patient to obtain test results. The patient must come for their first visit to receive the TST and then for a second visit, 48 to 72 hours later, to have their TST reaction read.

Since IGRAs are blood tests conducted in a laboratory, the patient is not exposed to the antigens. Thus, unlike the TST, there is no booster phenomenon when using an IGRA. Since IGRAs do not cause the booster phenomenon, there is no need to use two-step testing. (The booster phenomenon and two-step testing are discussed in the TB Testing Program section of this module.)

Another advantage of using IGRAs is that there is less chance of error in reading the result since it is a laboratory-based test. The TST requires that the health care worker place, measure, and interpret the test. Thus, there is more of a chance of an incorrect reading of TST results.

The antigens used in IGRAs are not found in the BCG vaccine strains. Therefore, previous vaccination with BCG will not cause false-positive results when using an IGRA.
### Table 3.6 Advantages of using an IGRA compared to using the TST.

<table>
<thead>
<tr>
<th>IGRA</th>
<th>TST</th>
</tr>
</thead>
<tbody>
<tr>
<td>Requires one patient visit to conduct the test</td>
<td>Requires at least two patient visits to conduct the test</td>
</tr>
<tr>
<td>Results can be available in 24 hours</td>
<td>Results are available 48 to 72 hours later</td>
</tr>
<tr>
<td>Does not cause booster phenomenon</td>
<td>Can cause booster phenomenon</td>
</tr>
<tr>
<td>Laboratory test not affected by health care worker perception or bias</td>
<td>Reading by health care worker may be subjective</td>
</tr>
<tr>
<td>Previous BCG vaccination does not cause false-positive result</td>
<td>Previous BCG vaccination may cause false-positive result</td>
</tr>
</tbody>
</table>

### Disadvantages and Limitations of IGRAs

There is still limited laboratory and medical experience with using IGRAs. The following are some known disadvantages and limitations to using IGRAs:

- Blood samples must be processed within 8 to 30 hours after collection.
- Errors in collecting or transporting blood specimens or in running and interpreting the test can decrease the accuracy of IGRAs.
- There is limited data on the use of IGRAs to predict who will progress to TB disease in the future.
- There are limited data on the use of IGRAs in
  - Children younger than 5 years of age,
  - Persons recently exposed to *M. tuberculosis*,
  - Immunocompromised persons, and
  - Serial testing.
- Tests may be expensive.
Module 3 — Targeted Testing and the Diagnosis of Latent Tuberculosis Infection and Tuberculosis Disease

Figure 3.4 QFT-GIT testing materials.

Figure 3.5 T-SPOT®.TB testing materials.
Study Questions 3.15–3.18

3.15 What are the steps for conducting an IGRA?

3.16 How are IGRA results interpreted?

3.17 How should a negative IGRA result be interpreted?

3.18 What are five advantages for using IGRAs as compared to the TST?

Answers to study questions are on pages 73–80
Many residential facilities, health care facilities, and other settings have **TB testing programs**. This means that employees and residents are periodically given TSTs or IGRAs. The purposes of the testing programs are to:

- Identify people who have LTBI and possibly TB disease, so that they can be given treatment as needed
- Determine whether TB is being transmitted in the facility

In a TB testing program, employees or residents are TB tested when they start their job or enter the facility. If they are using a TST, this is called the **baseline skin test**. If they have a negative test result, the employee or resident may be retested at regular intervals thereafter. In some facilities, repeat testing should be done at least once a year. For more information on TB testing programs at health care and residential facilities, please refer to *Module 5, Infectiousness and Infection Control*.

Employees or residents whose test results convert from negative to positive between testing intervals may have become infected with *M. tuberculosis*. These test conversions may indicate that TB is being transmitted in the facility. People with test conversions are at high risk of developing TB disease because they were infected with *M. tuberculosis* relatively recently. In order to detect TB transmission and identify people who have test conversions, it is important to keep accurate information on every employee’s baseline test, and subsequent tests.

**The Booster Phenomenon**

One factor that can affect the accuracy of the baseline skin test is the **booster phenomenon**. The booster phenomenon happens because in some people who have TB infection, the ability to react to tuberculin lessens over time. When these people are skin tested many years after they become infected with *M. tuberculosis*, they may have a negative reaction. However, if they are tested again within a year of the first test, they may have a positive reaction. This is because the first skin test “jogged the memory” of the immune system, **boosting** its ability to react to tuberculin. It may appear that these people were infected between the first and second skin tests; however, the second reaction is actually a **boosted reaction** (due to TB infection that occurred a long time ago). The booster phenomenon occurs mainly among older adults. Figure 3.6 illustrates the booster phenomenon.
IGRAs do not boost subsequent test results because, unlike the TST, the patient is not exposed to the *M. tuberculosis* antigens. However, the TST can boost a subsequent IGRA. Therefore, if a person will be tested with both the TST and an IGRA, it is recommended to conduct the IGRA either before or at the same time as the TST.

---

**Figure 3.6** The booster phenomenon with the TST.
The booster phenomenon can present a problem in TB testing programs. This is because a negative reaction to the baseline skin test, followed by a positive reaction to a subsequent skin test that is given up to a year later, may be caused by either

- **Recent TB infection** in a person who was NOT infected at the time of the baseline skin test, or
- A **boosted reaction** in a person who WAS already infected before the baseline skin test.

**Two-Step Testing with the TST**

To avoid misinterpretation, a strategy called **two-step testing** has been developed for telling the difference between boosted reactions and reactions caused by recent infection. Two-step testing should be used for the initial skin testing of persons who will be retested periodically, such as health care workers.

If a person has a negative reaction to an initial skin test, he or she is given a second test 1 to 3 weeks later.

- If the reaction to the second test is **positive**, it probably is a **boosted reaction** (due to TB infection that occurred a long time ago).
- If the reaction to the second test is **negative**, the person is considered **uninfected**. In this person, a positive reaction to a skin test given later on will probably be due to recent infection and be considered a **skin test conversion**.

Because two-step testing provides accurate information about an employee’s baseline skin test reaction, it is used in many TB testing programs for employees when they start their job. In particular, two-step testing is often used in hospitals and nursing homes. The procedure for two-step testing is shown in Figure 3.7.

Two-step testing is not required for IGRAs because IGRA testing does not boost subsequent test results.
Module 3—Targeted Testing and the Diagnosis of Latent Tuberculosis Infection and Tuberculosis Disease

Figure 3.7 Two-step testing with the TST.

Baseline Skin Test

Reaction

Negative

Retest 1–3 weeks later

Positive

Person probably has TB infection

Reaction

Negative

Person probably does NOT have TB infection

Positive

The reaction is considered a boosted reaction (due to TB infection that occurred a long time ago)

Repeat at regular intervals; a positive reaction will probably be due to a recent TB infection

Retesting not necessary
Study Questions 3.19–3.22

3.19 What is the booster phenomenon?

3.20 What is the purpose of two-step testing?

3.21 In what type of situation is two-step testing used?

3.22 How is two-step testing done?

Answers to study questions are on pages 73–80
Case Study 3.4

Ms. Wilson is a 60-year-old nurse. When she started a job at the local hospital, she was given a TST, her first test in 25 years. Her reaction was read 48 hours later as 0 millimeters of induration. Six months later, she was retested as part of the TB testing program in the unit where she works. Her skin test reaction was read 48 hours later as 11 millimeters of induration.

What are two ways to interpret this result?
Diagnosis of TB Disease

The key to diagnosing TB is for clinicians to “think TB” when they see a patient with symptoms of the disease or abnormal chest x-ray findings. Because TB is not as common as it was many years ago in the United States, many clinicians do not consider the possibility of TB when making diagnoses for patients who have symptoms of TB. When this happens, the diagnosis of TB may be delayed or even overlooked, and the patient will remain ill and possibly infectious.

Anyone with symptoms of TB or a positive TST or IGRA result should be medically evaluated for TB disease.

There are five components for conducting a complete medical evaluation for diagnosing TB disease.

1. Medical history
2. Physical examination
3. Test for TB infection
4. Chest x-ray
5. Bacteriological examinations

1. The Medical History

A medical history is the part of a patient’s life history that is important for diagnosing and treating the patient’s medical condition. It includes social, family, medical, and occupational information about the patient.

To obtain a medical history, the clinician should ask whether the patient has:

a. Any symptoms of TB disease
b. Been exposed to a person with infectious TB or has risk factors for exposure to TB
c. Risk factors for developing TB disease
d. Had LTBI or TB disease before
Clinicians should suspect the possibility of TB disease in patients with any of these factors.

**a. Symptoms of TB disease**

People with TB disease may or may not have symptoms. However, most patients with TB disease have one or more symptoms that led them to seek medical care. Occasionally, TB is discovered during a medical examination for an unrelated condition (for example, when a patient is given a chest x-ray before undergoing surgery). Usually, when patients do have symptoms, the symptoms have developed gradually, and they have been present for weeks or even months. General symptoms of TB disease include:

- Fever
- Chills
- Night sweats
- Weight loss
- Appetite loss
- Fatigue
- **Malaise**

Pulmonary TB disease usually causes one or more of the following symptoms:

- A cough lasting for 3 or more weeks
- Chest pain when breathing or coughing
- Coughing up sputum (phlegm from deep in the lungs) or blood

The symptoms of extrapulmonary TB disease depend on the part of the body that is affected by the disease. For example, TB of the spine may cause pain in the back; TB of the kidney may cause blood in the urine.

All of these symptoms may be caused by other diseases, but they should prompt the clinician to suspect the possibility of TB disease.

**b. Exposure to TB**

Another important part of the medical history is asking the patient about his or her exposure to TB. Patients should be asked whether they have spent time with someone who has infectious TB. Some people may have been exposed to TB in the distant past, when they were children. Others may have been exposed more recently.
Anyone who has been exposed to TB may have TB infection. Some people become infected with *M. tuberculosis* without knowing that they were exposed to it. The risk of being exposed to TB is higher for some people. It is important to consider demographic factors (for example, country of origin, age, ethnic or racial group, or occupation) that may increase the patient’s risk for exposure to TB.

**c. Risk factors for developing TB disease**

The third part of the medical history is checking for the patient’s risk factors for developing TB disease, including other medical conditions, especially HIV infection, which can increase the risk of LTBI progressing to TB disease. All patients who do not know their current HIV status should be referred for HIV counseling and testing.

For more information on factors and medical conditions that can increase the risk of patients developing TB disease, see the Targeted Testing section of this module.

**d. Previous TB infection or TB disease**

During the medical history, the clinician should ask the patient whether he or she has ever been diagnosed with or treated for TB infection or disease.

- Patients known to have a positive TST or IGRA result probably have TB infection. If they were infected within the past 2 years, they are at high-risk for developing TB disease.
- Patients who have had TB disease before should be asked when they had the disease and how the disease was treated.

Clinicians may also contact the local health department for information about whether a patient has received TB treatment in the past. If the treatment regimen that was prescribed was inadequate or if the patient did not follow the recommended treatment, the TB disease may come back, and it may be resistant to one or more of the drugs used.

**2. Physical Examination**

A physical examination is an essential part of the evaluation of any patient. It cannot confirm or rule out TB disease, but it can provide valuable information about the patient’s overall condition and factors that may affect how TB disease is treated if it is diagnosed.
3. Testing for TB Infection

Currently, there are two methods available for diagnosing TB infection in the United States:

- Mantoux tuberculin skin test (TST)
- Interferon-gamma release assays (IGRAs)
  - QuantiFERON®-TB Gold In-Tube test (QFT-GIT)
  - T-SPOT.TB test

Patients with symptoms of TB disease are sometimes evaluated by TST or IGRA to detect infection with TB. However, some patients with TB disease may have a negative TST or IGRA result. **Patients with symptoms should always be evaluated for TB disease, regardless of their TST or IGRA results.** Furthermore, clinicians should not wait for TST or IGRA results before starting other diagnostic tests for patients with symptoms of TB disease. Instead, the clinician should place a TST or order an IGRA at the same time as the other steps in the diagnosis of TB disease.
3.23 What are the five components for conducting a medical evaluation for diagnosing TB disease?
Study Questions 3.24–3.26

3.24 What parts of a patient’s medical history should lead a clinician to suspect the possibility of TB?

3.25 What are the symptoms of pulmonary TB disease? What are the symptoms of extrapulmonary TB disease?

3.26 For patients with symptoms of TB disease, should clinicians wait for TST or IGRA results before starting other diagnostic tests?

Answers to study questions are on pages 73–80
4. The Chest X-Ray

The chest x-ray, or radiograph, is useful for diagnosing TB disease because pulmonary TB is the most common form of the disease. Usually, when a person has TB disease in the lungs, the chest x-ray appears abnormal (Figure 3.8). It may show infiltrates (collections of fluid and cells in the tissues of the lung) or cavities (hollow spaces within the lung that may contain many tubercle bacilli).

The purposes of the chest x-ray are to
- Help rule out the possibility of pulmonary TB disease in a person who has a positive TST or IGRA result
- Check for lung abnormalities in people who have symptoms of TB disease

The results of a chest x-ray, however, cannot confirm that a person has TB disease. A variety of illnesses may produce abnormalities whose appearance on a chest x-ray resembles TB.

Figure 3.8 Abnormal chest x-ray. Arrow points to lower lobe cavity.
Although an abnormality on a chest x-ray may lead a clinician to suspect TB, **only a bacteriologic culture that is positive for *M. tuberculosis* confirms that a patient has TB disease.** Moreover, a chest x-ray cannot detect TB infection.

In persons living with HIV, pulmonary TB disease may have an unusual appearance on the chest x-ray. The chest x-ray may even appear entirely normal.

A chest x-ray may be used to rule out the possibility of pulmonary TB in a person who has had a positive TST or IGRA result and no symptoms of disease.
3.27 Name two purposes of the chest x-ray.

3.28 Can the results of a chest x-ray confirm that a person has TB disease? Why or why not?
5. The Bacteriologic Examination

Clinical specimens (for example, sputum or urine) are examined and cultured (grown) in the laboratory for the bacteriologic examination. TB bacteriologic examination is done in a laboratory that specifically deals with *M. tuberculosis* and other mycobacteria (a mycobacteriology laboratory). The bacteriologic examination has five parts:

a. Specimen collection
b. Examination of smears for acid-fast bacilli
c. Direct detection of *M. tuberculosis* in the specimen using a nucleic acid amplification test
d. Specimen culturing and identification of growth
e. Drug susceptibility testing

a. Specimen collection

Specimens that will be sent to the laboratory can be obtained in several ways. Usually, patients who are suspected of having pulmonary TB disease simply cough up sputum (phlegm from deep in the lungs) into a sterile container for processing and examination (Figure 3.9). This is the least expensive and easiest procedure. A health care worker should coach and directly supervise the patient when sputum is collected. Patients who are not supervised are not always successful in providing an adequate specimen, especially in their first attempt. The volume and quality of the specimen are critical for ensuring bacteriological examination is successful.
Patients should have at least three consecutive sputum specimens examined, each collected in 8 to 24-hour intervals. At least one should be collected early in the morning.

If a patient cannot cough up sputum on his or her own, other techniques can be used to obtain a specimen. An induced sputum sample can be obtained by having the patient inhale a saline (salt water) mist, which causes the patient to cough deeply. Induced specimens are often clear and watery; they should be labeled “induced specimen” so that they will not be confused with saliva. Laboratories will not accept saliva as a specimen.

Another procedure, bronchoscopy, can be used to obtain pulmonary secretions or lung tissue. In this procedure, an instrument called the bronchoscope is passed through the mouth directly into the diseased portion of the lung, and some sputum or lung tissue is removed. Bronchoscopy should be used only when patients cannot cough up sputum on their own and an induced specimen cannot be obtained.
A fourth procedure, **gastric washing**, involves inserting a tube through the patient’s nose and passing it into the stomach. The idea is to get a sample of gastric secretions that contains sputum that has been coughed into the throat and then swallowed. Gastric washings are done in the morning because patients usually swallow sputum during the night. This procedure is usually used only when patients cannot cough up sputum on their own, an induced specimen cannot be obtained, and bronchoscopy cannot be done. However, gastric washings are often used for obtaining samples from children. Most children produce little or no sputum when they cough.

It is very important for health care workers to use infection control precautions to control the spread of tubercle bacilli during sputum collection procedures. This is discussed further in Module 5, *Infectiousness and Infection Control*.

In patients who have extrapulmonary TB disease, specimens other than sputum may be obtained. The specimen obtained from these patients depends on the part of the body that is affected. For example, urine samples are obtained from patients suspected of having TB disease of the kidney, and fluid samples are obtained from the area around the spine in patients suspected of having TB meningitis (TB disease in the membranes surrounding the brain and spinal cord).

The methods of obtaining a sputum specimen are summarized in Table 3.7.
<table>
<thead>
<tr>
<th>Method</th>
<th>Description</th>
<th>Advantages</th>
<th>Disadvantages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Coughing up sputum</td>
<td>Patient coughs up sputum</td>
<td>Inexpensive</td>
<td>Patient may not be able to cough up sputum on his or her own, or may spit up saliva instead of sputum</td>
</tr>
<tr>
<td>Inducing sputum</td>
<td>Patient inhales a saline mist, causing him or her to cough deeply</td>
<td>Easy to do</td>
<td>Specimens may be watery and may be confused with saliva (should be labeled “induced specimen”) Requires special equipment</td>
</tr>
<tr>
<td>Bronchoscopy</td>
<td>Bronchoscope is passed through the mouth or nose directly into the diseased portion of the lung, and some sputum or lung tissue is removed</td>
<td>Useful for obtaining sputum when coughing or inducing sputum does not work</td>
<td>Most expensive and invasive procedure Requires special equipment Must be done by a specialized physician in a hospital or clinic</td>
</tr>
<tr>
<td>Gastric washing</td>
<td>Tube is inserted through the patient’s nose and passed into the stomach to get a sample of gastric secretions that contain sputum that has been coughed into the throat and then swallowed</td>
<td>Useful for obtaining samples in children, who usually produce little or no sputum when they cough</td>
<td>Must be done as soon as patient wakes up in the morning; patient may be required to stay in hospital Can be uncomfortable for the patient</td>
</tr>
</tbody>
</table>
Case Study 3.5

Mr. Lee has a cough and other symptoms of TB disease, and he is evaluated with a chest x-ray. However, he is unable to cough up any sputum on his own for the bacteriologic examination.

What should be done?
b. Examination of AFB smears

Before the specimen is examined under a microscope, it may undergo processing to break up the sample and kill other organisms that may be present. A sample is smeared onto a glass slide and stained with a dye. This is called a smear. Then laboratory personnel use a microscope to look for acid-fast bacilli (AFB) on the smear (Figure 3.10). AFB are mycobacteria that stay stained even after they have been washed in an acid solution. Tubercle bacilli are one kind of AFB.

When AFB are seen in a smear, they are counted. There is a system for reporting the number of AFB that are seen at a certain magnification. According to the number of AFB seen, the smears are classified as 4+, 3+, 2+, or 1+. In smears classified as 4+, 10 times as many AFB were seen as in smears classified as 3+; in 3+ smears, 10 times as many as in 2+ smears; and in 2+ smears, 10 times as many as in 1+ smears.

Smears that are classified as 4+ and 3+ are considered strongly positive; 2+ and 1+ smears are considered moderately positive. If very few AFB are seen, the smear is classified by the actual number of AFB seen (no plus sign). For example, if only 2 AFB were seen in the entire smear, the smear is classified as “2 AFB seen.” Smears classified in this way are considered weakly positive, and the smear should be repeated. Finally, if no AFB are seen, the smear is called negative. But a negative smear does not rule out the possibility of TB because there can be AFB in the smear that were not seen.
It takes only a few hours to prepare and examine a smear. Therefore, the results of the smear examination should be available to the clinician within 1 day.

The results of the smear examination can be used to help determine the infectiousness of the patient. Patients who have many tubercle bacilli in their sputum have a positive smear. Patients who have positive smears are considered infectious because they can cough many tubercle bacilli into the air. (This is discussed in more detail in Module 5, Infectiousness and Infection Control.) However, because AFB are not always tubercle bacilli, patients who have positive smears do not necessarily have TB. Furthermore, as mentioned previously, patients who have negative smears may have TB.

The classification of smears is summarized in Table 3.8.

### Table 3.8 Smear classifications and results.

<table>
<thead>
<tr>
<th>Classification of Smear</th>
<th>Smear Result</th>
<th>Infectiousness of Patient</th>
</tr>
</thead>
<tbody>
<tr>
<td>4+</td>
<td>Strongly positive</td>
<td>Probably very infectious</td>
</tr>
<tr>
<td>3+</td>
<td>Strongly positive</td>
<td>Probably very infectious</td>
</tr>
<tr>
<td>2+</td>
<td>Moderately positive</td>
<td>Probably infectious</td>
</tr>
<tr>
<td>1+</td>
<td>Moderately positive</td>
<td>Probably infectious</td>
</tr>
<tr>
<td>Actual number of AFB seen (no plus sign)</td>
<td>Weakly positive</td>
<td>Probably infectious</td>
</tr>
<tr>
<td>No AFB seen</td>
<td>Negative</td>
<td>May not be infectious*</td>
</tr>
</tbody>
</table>

* The criteria for determining whether a patient may be considered noninfectious are discussed in Module 5, Infectiousness and Infection Control.
Study Questions 3.29–3.31

3.29 What are the four ways to collect sputum specimens? Indicate which procedure is the least expensive and easiest to perform.

3.30 What do laboratory personnel look for in a smear?

3.31 What does a positive smear indicate about a patient’s infectiousness?

Answers to case studies are on pages 81–84
Case Study 3.6

Ms. Thompson gave three sputum specimens, which were sent to the laboratory for smear examination and culture. The smear results were reported as 4+, 3+, and 4+.

What do these results tell you about Ms. Thompson’s diagnosis and her infectiousness?

Answers to case studies are on pages 81–84
Case Study 3.7

Mr. Sagoo has symptoms of TB disease and a cavity on his chest x-ray, but all of his sputum smears are negative for acid-fast bacilli.

Does this rule out the diagnosis of pulmonary TB disease?

Why or why not?
c. Direct detection of *M. tuberculosis* in the specimen by nucleic acid amplification test

**Nucleic acid amplification (NAA) tests can be used to detect* M. tuberculosis* from sputum specimens.**

NAA tests, including polymerase chain reaction (PCR) and other methods, rapidly identify the microorganisms in the specimen by amplifying (copying) DNA and RNA segments. NAA testing should be performed on at least one respiratory specimen from a patient with signs and symptoms of pulmonary TB for whom a diagnosis of TB is being considered, and for whom the test result would alter case management or TB control activities.

A patient can be presumed to have TB if he or she has a positive NAA test with an AFB positive smear. If a patient has a negative NAA test with an AFB positive smear, he or she may have a nontuberculous mycobacteria (NTM) infection. NAA test results can help guide clinicians’ decisions for patient therapy and isolation; however, NAA tests do not replace the need for AFB smear, culture, or clinical judgment.

For more information about NAA tests, refer to the CDC’s *Updated Guidelines for the Use of Nucleic Acid Amplification Tests in the Diagnosis of Tuberculosis*, available from the CDC website ([www.cdc.gov/tb](http://www.cdc.gov/tb)).

**The Xpert MTB/RIF assay simultaneously detects* Mycobacterium tuberculosis complex* and resistance to rifampin in less than 2 hours.**

The Xpert MTB/RIF assay is an NAA test that simultaneously detects *M. tuberculosis* complex and resistance to rifampin, one of the most effective drugs used to treat TB.

To conduct the Xpert MTB/RIF assay, a sputum sample is mixed with a sterilizing reagent that is provided with the assay, and a cartridge containing the mixture is placed in the GeneXpert machine. Results from the test are available in less than 2 hours.

Results that are positive for *M. tuberculosis* complex and for rifampin resistance indicate that the bacteria have a high probability of resistance to rifampin. This result should be confirmed by additional rapid testing. If rifampin resistance is confirmed, rapid molecular testing for drug resistance to both first-line and second-line drugs should be performed so that an effective treatment regimen can be selected. Growth-based drug susceptibility testing should be performed as well. Growth-based susceptibility testing is discussed in more detail on page 65 of this module.
Results that are positive for *M. tuberculosis* complex, but negative for rifampin resistance mean that the bacteria are probably susceptible to rifampin. However, all tests that are positive for *M. tuberculosis* complex should have growth-based drug susceptibility testing to first-line TB drugs.

Results that are positive for *M. tuberculosis* complex and indeterminate for rifampin resistance mean that the test could not accurately determine if the bacteria are resistant.

As with other NAA tests, the Xpert MTB/RIF assay should be interpreted along with clinical, radiographic, and other laboratory findings. The Xpert MTB/RIF assay does not replace the need for AFB smear microscopy, culture for mycobacteria, growth-based drug susceptibility testing, and genotyping. Providers and laboratories need to ensure that patient specimens are available for all recommended mycobacterial testing.


**d. Culturing and identifying growth from the specimen**

Culturing the specimen means growing the mycobacteria on solid or in liquid media (Figure 3.12). When the mycobacteria have formed colonies (groups), or when there is sufficient growth in the liquid media, they can be identified. All specimens should be cultured, regardless of whether the smear is positive or negative.

*Culturing the specimen is necessary to determine if it contains* *M. tuberculosis* *and to confirm a diagnosis of TB disease.* Additionally, culture is necessary to perform further drug susceptibility testing and genotyping.

In some instances, patients are diagnosed with TB disease on the basis of their clinical presentation (i.e., signs and symptoms, response to treatment), even if their culture is negative.
Figure 3.11 NAA test kit.

Figure 3.12 Colonies of *M. tuberculosis* growing on solid media.
The first procedure in culturing the specimen is to detect the growth of the mycobacteria. Mycobacteria grow very slowly. When solid media are used to culture the specimen, it can take as long as 3 to 6 weeks for the growth of the mycobacteria to be detected. However, rapid culturing methods that involve liquid media can decrease this time to 4 to 14 days.

The second procedure is to identify the organism that has grown in the culture. All types of mycobacteria will grow in solid or liquid media. For this reason, laboratory tests must be done to determine whether the organism is \textit{M. tuberculosis} or one of the nontuberculous mycobacteria. Nucleic acid probes can rapidly identify the type of mycobacteria present in the specimens in 2 to 4 hours. Thus, using liquid media and nucleic acid probes, it is usually possible to culture and to identify \textit{M. tuberculosis} within three weeks.

When \textit{M. tuberculosis} is identified in a patient’s culture, the patient is said to have a positive culture for \textit{M. tuberculosis}. A positive culture for \textit{M. tuberculosis}, also called an \textit{M. tuberculosis} isolate, confirms the diagnosis of TB disease.

When \textit{M. tuberculosis} is NOT identified in a patient’s culture, the patient is said to have a negative culture for \textit{M. tuberculosis}. A negative culture does not necessarily rule out the diagnosis of TB disease; as mentioned earlier, some patients with negative cultures are diagnosed with TB disease on the basis of their clinical presentation (i.e., signs and symptoms, response to treatment).

Follow-up bacteriological examinations are important for assessing the patient’s infectiousness and response to treatment. Specimens should be obtained monthly until 2 consecutive specimen cultures are negative. Culture conversion is the most important objective measure of response to treatment.

Laboratories should report positive results on smears and cultures within 24 hours by telephone or fax to the primary health care provider and to the state or local TB control program, as required by law. Out-of-state laboratories who receive referral specimens must contact the health care provider in the patient’s state of origin. Follow-up results may be reported by mail. It is the responsibility of the primary health care provider to promptly report all suspected or confirmed cases of TB to the state or local health department, unless state laws indicate otherwise. This will ensure that a contact investigation can be initiated quickly to interrupt the potential ongoing transmission.
The differences between sputum smears and cultures are summarized in Table 3.9.

**Table 3.9 Differences between sputum smears and cultures.**

<table>
<thead>
<tr>
<th>Feature</th>
<th>Smears</th>
<th>Cultures</th>
</tr>
</thead>
<tbody>
<tr>
<td>Equipment needed</td>
<td>Microscope, glass slides, special dyes</td>
<td>Incubators, biosafety cabinet, culture plates or tubes, culture media</td>
</tr>
<tr>
<td>Time needed to make report</td>
<td>1 day</td>
<td>4 days to 8 weeks (depending on method used and how quickly the organism grows)</td>
</tr>
<tr>
<td>Basis of procedure</td>
<td>Looking for AFB on slide under microscope</td>
<td>Growth and identification of tubercle bacilli or other mycobacteria on culture media</td>
</tr>
<tr>
<td>Significance of a negative report</td>
<td>Patient is less likely to be infectious</td>
<td>No live tubercle bacilli found in the specimen</td>
</tr>
<tr>
<td></td>
<td>Does not rule out TB disease (culture may be positive)</td>
<td>Does not rule out TB disease (live tubercle bacilli may be in other specimens or in the patient)</td>
</tr>
<tr>
<td>Significance of a positive report</td>
<td>Patient is more likely to be infectious (if AFB are tubercle bacilli)</td>
<td>Confirms diagnosis of TB disease</td>
</tr>
<tr>
<td></td>
<td>AFB could be nontuberculous mycobacteria</td>
<td></td>
</tr>
</tbody>
</table>
Criteria for Reporting TB Cases

All 50 states, the District of Columbia, New York City, Puerto Rico, and seven other jurisdictions in the Pacific and the Caribbean report TB cases to the federal Centers for Disease Control and Prevention (CDC) using a standard case report form called the Report of Verified Case of Tuberculosis (RVCT). Each reported TB case is checked to make sure that it meets certain criteria. All cases that meet the criteria, called verified TB cases, are counted each year.

Cases that meet one of these four sets of criteria are counted as verified TB cases:

1. The patient has a positive culture for *M. tuberculosis*.

   or

2. The patient has a positive NAA test for *M. tuberculosis*.*

   or

3. The patient has a positive smear for AFB, but a culture has not been or cannot be obtained or is falsely negative or contaminated.

   or

4. If in the absence of laboratory confirmation, the patient meets all of the following criteria:
   - A positive TST or IGRA,
   - Other signs and symptoms of TB disease (e.g., abnormal chest x-ray, fever, night sweats, cough, weight loss, hemoptysis),
   - Treatment with two or more anti-TB drugs, and
   - A completed diagnostic evaluation.

5. In addition, cases that do not meet any of these sets of criteria (for example, a patient who is anergic and has a negative culture for *M. tuberculosis* but who has signs and symptoms of TB disease) may be counted as a verified TB case if a health care provider has reported the case and decided to treat the patient for TB disease.

*Nucleic acid amplification (NAA) tests must be accompanied by culture for mycobacteria species. However, for surveillance purposes, CDC will accept results obtained from NAA tests approved by the Food and Drug Administration (FDA) and used according to the approved product labeling on the package insert, or a test produced and validated in accordance with applicable FDA and Clinical Laboratory Improvement Amendments (CLIA) regulations.
e. Drug susceptibility testing

For all patients, drug susceptibility tests should be done when the patient is first found to have a positive culture for *M. tuberculosis* (that is, the first isolate of *M. tuberculosis*). Drug susceptibility tests are done to determine which drugs will kill the tubercle bacilli that are causing disease in a particular patient. Tubercle bacilli that are killed by a particular drug are said to be **susceptible** to that drug, whereas those that can grow even in the presence of a particular drug are said to be **resistant** to that drug. The **drug susceptibility pattern** of a strain of tubercle bacilli is the list of drugs to which the strain is susceptible and to which it is resistant. The initial isolate should be tested for resistance to the first-line anti-TB drugs: rifampin, isoniazid, ethambutol, and pyrazinamide.

Drug-resistant TB can be **mono-resistant** if the tubercle bacilli are resistant to any one TB treatment drug, or **poly-resistant** if resistant to at least two TB drugs (but not both isoniazid and rifampin). A patient is diagnosed with **multidrug-resistant TB (MDR TB)** if the tubercle bacilli are resistant to at least isoniazid and rifampin, the two best first-line TB treatment drugs. A patient is diagnosed with **extensively drug-resistant TB (XDR TB)** if the tubercle bacilli are resistant to isoniazid and rifampin, plus resistant to any fluoroquinolone and at least one of three injectable anti-TB drugs (such as amikacin, kanamycin, or capreomycin).

The results of drug susceptibility tests can help clinicians choose the appropriate drugs for each patient. This is very important. Patients with TB disease who are treated with drugs to which their strain of TB is resistant may not be cured. In fact, their strain of TB may become resistant to additional drugs.

Drug susceptibility tests should be repeated if a patient has a positive culture for *M. tuberculosis* after 3 months of treatment or if a patient does not seem to be getting better.
**Growth-Based Drug Susceptibility Testing**

Growth-based drug susceptibility testing can be done using a liquid medium or a solid medium method. In a drug susceptibility test, organisms that grow in media containing a specific drug are considered resistant to that drug (Figure 3.13). Liquid medium methods are faster than solid media methods for determining susceptibility to first-line TB medications (Figure 3.14). Usually the susceptibility results can be obtained within 7 to 14 days with the liquid medium method. Traditional solid medium methods can take as long as 21 days.

**Molecular Detection of Drug Resistance**

Drug resistance is due to the presence of mutations in specific *M. tuberculosis* genes. There are a variety of tests that can detect mutations associated with drug resistance. The tests are done on patient specimens or isolates from patient specimens. If a mutation thought to be associated with resistance is detected, the bacteria are considered to be drug resistant. Molecular tests can provide results within 24 to 48 hours.

A limitation of molecular testing for drug resistance is that the clinical relevance of some mutations remains unknown. Further, not all biological mechanisms of resistance are known. As a result, if no mutations are detected by the molecular test, drug resistance cannot be ruled out. **Therefore, it is essential that conventional growth-based drug susceptibility tests are done and used in conjunction with molecular results.**

Molecular tests provide **preliminary** guidance on effective therapy for TB patients. Molecular detection of drug resistance should be considered for patients with the following characteristics:

- High risk of rifampin resistance, including MDR TB (e.g., previously treated for TB, contact to someone with MDR TB, or foreign-born from a high-risk country);
- First-line drug susceptibility results are available and show resistance to rifampin;
- Infectiousness poses a risk to vulnerable contacts (e.g., infants); and
- Contraindications to essential first-line medications (e.g., rifampin allergy).
Figure 3.13 Drug susceptibility testing on solid media. Organisms are resistant to the drug in the upper right compartment and susceptible to the drugs in the lower compartments. Upper left contains no drugs.

Figure 3.14 Drug susceptibility testing in liquid media.
Study Questions 3.32–3.35

3.32 Why is it necessary to culture a specimen?

3.33 What does a positive culture for *M. tuberculosis* mean? How is this important for the TB diagnosis?

3.34 Why are drug susceptibility tests done?

3.35 How often should drug susceptibility tests be done?

Answers to study questions are on pages 73–80
In the public health clinic, you see a patient, Ms. Sanchez, who complains of weight loss, fever, and a cough of 4 weeks duration. When questioned, she reports that she has been treated for TB disease in the past and that she occasionally injects heroin.

What parts of Ms. Sanchez's medical history lead you to suspect TB disease?

What diagnostic tests should be done?

Answers to case studies are on pages 81–84.
TB Genotyping

TB genotyping is a laboratory-based method that can determine the genetic pattern of the strain of *M. tuberculosis* that caused TB disease in a person. Each strain has a distinct genetic pattern, or genotype. Genotyping is done for culture-positive cases of TB disease. TB programs should work with laboratories to ensure that TB genotyping results are obtained for all culture-positive cases.

Genotyping has applications at both the population level and the individual patient level. At the population level, genotyping is most commonly used for detecting, refuting, and monitoring TB outbreaks. For more information about the use of genotyping in TB outbreaks, refer to Module 9, *Tuberculosis Outbreak Detection and Response*.

At the patient level, TB genotyping has three uses:
- Distinguishing relapse from reinfection
- Detecting false-positive culture results
- Informing contact investigations

### Distinguishing Relapse from Reinfection

Some patients previously treated for TB disease may develop TB disease again. This could be due to a relapse or reinfection. Genotyping results can be used to distinguish relapse from reinfection.

Recurrence of TB disease after treatment is most often due to relapse of TB disease. Relapse can occur for several reasons including inappropriate treatment, nonadherence to treatment, or unidentified drug resistance. If genotype information from the first episode of TB is available, it can be compared with genotype information from the second episode. If the genotypes match, it is likely the TB disease was not completely cured the first time it was treated.

If the genotypes from the two episodes of TB disease do not match, it is likely the second episode occurred because the person became infected with a different strain of *M. tuberculosis* (reinfection).
Detecting False-Positive Cultures

Genotype information can alert laboratory and public health staff to situations where specimens from different patients, processed within the same facility and time period, share genotypes. When this situation occurs, the laboratory can follow a process to determine if an error has been made, and one or more of the cultures are falsely positive. False-positive TB cultures can be caused by cross-contamination of a specimen in the laboratory, clerical error such as mislabeling of specimens, or contaminated equipment such as a bronchoscope used to collect the samples.

Identifying false-positive cultures is important because doing so helps prevent unnecessary treatment and contact investigations for persons who would otherwise be misdiagnosed with TB disease.

Informing Contact Investigations

Typically, genotype information will not be available during the early stages of a contact investigation; however, when it is available, genotype results can help confirm, disprove, or detect connections among patients. For more information about the use of genotyping in contact investigations, refer to Module 8, Contact Investigations for Tuberculosis.
Additional Resources


3. CDC. Availability of an Assay for Detecting Mycobacterium tuberculosis, Including Rifampin-Resistant Strains, and Considerations for Its Use—United States, 2013. MMWR 2013;62 (41). [www.cdc.gov/mmwr/preview/mmwrhtml/mm6241a1.htm?c_id=mm6241a1_e](http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6241a1.htm?c_id=mm6241a1_e).


7. CDC. Mantoux Tuberculin Skin Test [DVD]. Atlanta, Ga: Department of Health and Human Services, CDC; March 2005. [www.cdc.gov/tb/education/Mantoux/default.htm](http://www.cdc.gov/tb/education/Mantoux/default.htm).


11. CDC. Updated Guidelines for the Use of Nucleic Acid Amplification Tests in the Diagnosis of Tuberculosis. MMWR 2009; 58 (1). www.cdc.gov/mmwr/preview/mmwrhtml/mm5801a3.htm?scid=mm5801a3_e.


Answers to Study Questions

3.1. What is the TST used for?
The TST is used to determine whether a person has TB infection.

3.2. How is the TST given?
The TST is given by using a needle and syringe to inject 0.1 ml of 5 tuberculin units of liquid tuberculin between the layers of the skin (intradermally), usually on the forearm.

3.3. With the TST, when is the patient’s arm examined?
The patient’s arm is examined 48 to 72 hours after the tuberculin is injected.

3.4. How is the induration measured?
The diameter of the indurated area is measured across the forearm; erythema (redness) around the indurated area is not measured, because the presence of erythema does not indicate that a person has TB infection.

3.5. What two factors determine the interpretation of a TST reaction as positive or negative? What additional factor is considered for people who may be exposed to TB on the job?
The two factors that are used to determine the interpretation of a TST include the size of the induration and the person’s risk factors for TB.

For people who may be exposed to TB on the job, an additional factor that is considered is the risk of exposure to TB in the person’s job.

3.6. Name five groups of people for which 5 or more millimeters of induration is considered a positive reaction.
An induration of 5 or more millimeters is considered a positive reaction for

- People living with HIV
- Recent contacts of people with infectious TB
- People with chest x-ray findings suggestive of previous TB disease
- People with organ transplants
- Other immunosuppressed patients (for example, patients on prolonged therapy with corticosteroids equivalent to/greater than 15mg per day of prednisone or those taking TNF-alpha antagonists)
Answers to Study Questions, Continued

3.7. Name seven groups of people for which 10 or more millimeters of induration is considered a positive reaction.

An induration of 10 or more millimeters is considered a positive reaction for:

- People who have recently come to the United States (within the last 5 years) from areas of the world where TB is common (for example, Asia, Africa, Russia, Eastern Europe, or Latin America)
- People who abuse drugs
- Mycobacteriology laboratory workers
- People who live or work in high-risk congregate settings (for example, nursing homes, homeless shelters, or correctional facilities)
- People with certain medical conditions that place them at high risk for TB (for example, silicosis, diabetes mellitus, severe kidney disease, certain types of cancer, and certain intestinal conditions)
- Children younger than 5 years of age
- Infants, children, or adolescents exposed to adults in high-risk categories

3.8. For which group of people is 15 or more millimeters of induration considered a positive reaction?

An induration of 15 or more millimeters is considered a positive reaction for people with no known risk factors for TB.

3.9. Name four factors that may cause false-positive reactions to the TST.

- Infection with nontuberculous mycobacteria (NTM) (mycobacteria other than \textit{M. tuberculosis})
- BCG vaccination
- Administration on incorrect antigen
- Incorrect measuring or interpretation of the TST reaction

3.10. Is there a reliable way to distinguish a positive TST reaction caused by vaccination with BCG from a reaction caused by true TB infection?

No, there is no reliable way to distinguish a positive TST reaction caused by vaccination with BCG from a reaction caused by true TB infection. When using the TST, people with a positive reaction who have been vaccinated with BCG should always be further evaluated for LTBI or TB disease the same as if they were not vaccinated with BCG.
3.11. Name six factors that may cause false-negative reactions to the TST.
False-negative reactions may be due to
- Anergy
- Recent TB infection (within the past 8 to 10 weeks)
- Very young age (younger than 6 months of age)
- Recent live-virus measles or smallpox vaccination
- Incorrect method of giving the TST
- Incorrect measuring or interpretation of TST reaction

3.12. What is anergy?
Anergy is the inability to react to skin tests because of a weakened immune system. Many conditions, such as HIV infection, cancer, or severe TB disease itself, may weaken the immune system and cause anergy. HIV infection is an important cause of anergy.

3.13. After TB has been transmitted, how long does it take before TB infection can be detected by the TST?
After TB has been transmitted, it takes 2 to 8 weeks before TB infection can be detected by the TST.

3.14. What should be done if a patient has a negative TST reaction but has symptoms of TB disease?
Any patient with symptoms of TB disease should be evaluated for TB disease, regardless of his or her skin test reaction. In fact, people with symptoms of TB disease should be evaluated for TB disease right away, at the same time that the TST is given.

3.15. What are the steps for conducting an IGRA?
To conduct an IGRA, health care workers should first read the instructions from the manufacturer and then follow the steps below:
- Confirm arrangements for testing in a qualified laboratory.
- Arrange for delivery of the blood sample to the laboratory in the time the laboratory specifies to ensure testing of samples with viable blood cells.
- Draw a blood sample from the patient according to the test manufacturer’s instructions.
- Schedule a follow-up appointment for the patient to receive test results.
- Based on test results, provide follow-up evaluation and treatment as needed.
3.16. How are IGRA results interpreted?
QFT-GIT results are based on the amount of IFN-γ that is released in response to the \textit{M. tuberculosis} antigens and control substances. T-Spot results are based on the number of IFN-γ producing cells (spots) produced. Both the standard qualitative test interpretation (positive, negative, or indeterminate) and the quantitative assay measurements (Nil, TB, and Mitogen concentrations or spot counts) should be reported.

3.17. How should negative IGRA results be interpreted?
If the result is negative, then the patient is unlikely to have \textit{M. tuberculosis} infection and may not require further evaluation unless they have signs and symptoms of TB disease. Moreover, as with the TST, persons who have a negative test result can still have LTBI.

3.18. What are five advantages for using IGRAs as compared to the TST?
- Requires a single patient visit to conduct the test
- Results can be available within 24 hours
- Does not cause the booster phenomenon which can happen with repeat TSTs
- Laboratory test not affected by health care worker perception or bias
- BCG vaccination does not affect IGRA results

3.19. What is the booster phenomenon?
The booster phenomenon is a phenomenon in which people (especially older adults) who are skin tested many years after becoming infected with \textit{M. tuberculosis} may have a negative reaction to an initial skin test, followed by a positive reaction to a skin test given up to a year later. This happens because in some people who have TB infection, the ability to react to tuberculin lessens over time. The first skin test “jogs the memory” of the immune system, boosting its ability to react to tuberculin.

3.20. What is the purpose of two-step testing?
The purpose of two-step testing is to tell the difference between boosted reactions and reactions caused by recent infection. Because it provides accurate information about each employee’s baseline skin test reaction, two-step testing is used in many TB screening programs for skin testing employees when they start their job.

3.21. In what type of situation is two-step testing used?
Two-step testing is used in many TB screening programs for skin testing employees when they start their job.
3.22. How is two-step testing done?

If a person has a negative reaction to an initial skin test, he or she is given a second test 1 to 3 weeks later.

- If the reaction to the second test is positive, it is considered a boosted reaction (due to TB infection that occurred a long time ago)
- If the reaction to the second test is negative, the person is considered uninfected. In this person, a positive reaction to a TST given later on will probably be due to recent TB infection.

3.23. What are the five components for conducting a complete medical evaluation for diagnosing TB disease?

- Medical history
- Physical examination
- Test for TB infection
- Chest x-ray
- Bacteriologic examinations

3.24. What parts of a patient’s medical history should lead a clinician to suspect the possibility of TB?

Clinicians should suspect the possibility of TB disease in patients who have

- Symptoms of TB disease
- Been exposed to a person who has infectious TB or has other risk factors for exposure to TB
- Risk factors for developing TB disease
- Had TB infection or TB disease before
3.25. **What are the symptoms of pulmonary TB disease? What are the symptoms of extrapulmonary TB disease?**

General symptoms of TB disease include:

- Fatigue
- Malaise
- Fever
- Weight loss
- Night sweats

Symptoms of pulmonary TB disease include:

- Coughing
- Pain in the chest when breathing or coughing
- Coughing up sputum or blood

The symptoms of extrapulmonary TB disease depend on the part of the body that is affected by the disease. For example, TB of the spine may cause pain in the back; TB of the kidney may cause blood in the urine.

3.26. **For patients with symptoms of TB disease, should clinicians wait for TST or IGRA results before starting other diagnostic tests?**

No. For patients with symptoms of TB disease, clinicians should not wait for TST or IGRA results before starting other diagnostic tests.

3.27. **Name two purposes of the chest x-ray.**

The purposes of the chest x-ray are to

- Help rule out the possibility of pulmonary TB disease in a person who has a positive TST or IGRA result and no symptoms of TB
- Check for lung abnormalities in people who have symptoms of TB disease

3.28. **Can the results of a chest x-ray confirm that a person has TB disease? Why or why not?**

No, the results of a chest x-ray cannot confirm that a person has TB disease. This is because a variety of illnesses may produce abnormalities whose appearance on a chest x-ray resembles TB. Although an abnormality on a chest x-ray may lead a clinician to suspect TB, only a bacteriologic culture that is positive for *M. tuberculosis* confirms that a patient has TB disease.
3.29. What are the four ways to collect sputum specimens? Indicate which procedure is the least expensive and easiest to perform.

- Usually, patients who are suspected of having pulmonary TB disease simply cough up sputum and the sputum is collected in a sterile container for processing and examination. This is the least expensive and easiest procedure. If a patient cannot cough up sputum on his or her own, other techniques can be used to obtain a specimen.
- An induced sputum sample can be obtained by having the patient inhale a saline (salt water) mist, which causes the patient to cough deeply.
- Bronchoscopy can be used to obtain pulmonary secretions or lung tissue. In this procedure, an instrument called the bronchoscope is passed through the nose or mouth directly into the diseased portion of the lung, and some sputum or lung tissue is removed.
- Gastric washing involves inserting a tube through the patient’s nose and passing it into the stomach. The idea is to get a sample of gastric secretions that contain sputum that has been coughed into the throat and then swallowed.

3.30. What do laboratory personnel look for in a smear?

Laboratory personnel use the microscope to look for acid-fast bacilli (AFB) on the smear. AFB are mycobacteria that stay stained even after they have been washed in an acid solution. Tubercle bacilli are one kind of AFB.

3.31. What does a positive smear indicate about a patient’s infectiousness?

The results of the smear examination can be used to help determine the infectiousness of the patient. Patients who have many tubercle bacilli in their sputum have a positive smear. Patients who have positive smears are considered infectious because they can cough many tubercle bacilli into the air.

3.32. Why is it necessary to culture a specimen?

Culturing the specimen is necessary to determine whether the specimen contains \textit{M. tuberculosis} and to confirm a diagnosis of TB disease. (However, in some cases, patients are diagnosed with TB disease on the basis of their signs and symptoms, even if their specimen does not contain \textit{M. tuberculosis}.) Additionally, culture is necessary for genotyping and for performing drug susceptibility testing.
3.33. What does a positive culture for *M. tuberculosis* mean? How is this important for the TB diagnosis?

A positive culture for *M. tuberculosis* means that *M. tuberculosis* has been identified in a patient’s culture. A positive culture for *M. tuberculosis* confirms the diagnosis of TB disease.

3.34. Why are drug susceptibility tests done?

Drug susceptibility tests are done to determine which drugs will kill the tubercle bacilli that are causing disease in a particular patient. The results of drug susceptibility tests can help clinicians choose the appropriate drugs for each patient.

3.35. How often should drug susceptibility tests be done?

Drug susceptibility tests should be done when a patient is first found to have a positive culture for *M. tuberculosis*. In addition, drug susceptibility tests should be repeated if a patient has a positive culture for *M. tuberculosis* after 3 months of treatment or if a patient does not seem to be getting better.
Case Study Answers

3.1 Which of the following patients have a positive TST reaction? Circle the best answer(s).

a) Mr. West, 36 years old, HIV infected, 8 mm of induration

b) Ms. Hernandez, 26 years old, native of Mexico, 7 mm of induration

c) Ms. Jones, 56 years old, has diabetes, 12 mm of induration

d) Mr. Sung, 79 years old, resident of a nursing home, 11 mm of induration

e) Mr. Williams, 21 years old, no known risk factors, 13 mm of induration

f) Ms. Marcos, 42 years old, chest x-ray findings suggestive of previous TB, 6 mm of induration

g) Ms. Rayle, 50 years old, husband has pulmonary TB, 9 mm of induration

A, C, D, F, and G all have positive TST reactions.
Case Study Answers, Continued

3.2. A 30-year-old man who recently immigrated to the United States from India is given a TST and found to have 14 millimeters of induration. He reports that he was vaccinated with BCG as a child. He also says that his wife was treated for pulmonary TB disease last year.

How should this man’s results be interpreted?

This man has a positive reaction to the TST (10 or more millimeters is considered a positive reaction for a person from a country where TB is common). Also, he is a contact of person with pulmonary TB (his wife). Because he was vaccinated with BCG there is a possibility that this may be a false-positive reaction. However, since there is no reliable way to distinguish a positive TST reaction caused by BCG or from a true TB infection, this man should be further evaluated for LTBI or TB disease as if he was never vaccinated with BCG.

What factors make it more likely that this man’s positive reaction is due to TB infection?

This man is from an area of the world where TB is common, so he was probably exposed to TB in his native country. Therefore, he is at increased risk for TB infection. Also, his wife has had pulmonary TB, which further increases the probability that he has been exposed to TB. Since there is no reliable way to distinguish a positive TST reaction caused by BCG from a true TB infection, this man should be further evaluated for LTBI or TB disease as if he was never vaccinated with BCG.

3.3. Mr. Bell comes to the TB clinic for a TST. He believes that he has been exposed to TB, and he knows he is at high risk for TB because he is HIV-infected. He is given a TST, and his reaction is read 48 hours later as 0 millimeters of induration.

What are three ways to interpret this result?

There are three possible reasons why Mr. Bell had no reaction to the tuberculin skin test.

- First, he may not have TB infection.
- Second, he may be anergic. People who are HIV-infected are more likely to be anergic than persons who are not HIV-infected. If Mr. Bell is anergic, he would be unable to react to tuberculin even if he did have TB infection.
- Third, it may be less than 8 to 10 weeks since he was exposed to TB. After TB has been transmitted, it takes 2 to 8 weeks before TB infection can be detected by the TST. Mr. Bell should be retested 8 to 10 weeks after he was last exposed to TB.
3.4. **Ms. Wilson is a 60-year-old nurse.** When she started a job at the local hospital, she was given a TST, her first test in 25 years. Her reaction was read 48 hours later as 0 millimeters of induration. Six months later, she was retested as part of the TB screening program in the unit where she works. Her TST reaction was read 48 hours later as 11 millimeters of induration.

**What are two ways to interpret this result?**

There are two possible explanations for this result.

- One explanation is that Ms. Wilson may have been exposed to and infected with *M. tuberculosis* sometime in the 6 months between her first and second skin tests.
- The other explanation is the booster phenomenon. If Ms. Wilson was infected with *M. tuberculosis* many years ago, her ability to react to tuberculin may have decreased. This would explain why she did not react to the first TST. Then the first tuberculin test may have boosted the ability of her immune system to react to tuberculin. This would explain why she had a positive reaction to the second TST, which was given within a year of the first test. If this scenario is true, Ms. Wilson’s positive reaction would not mean that she was recently infected with *M. tuberculosis*.

This problem in interpreting Ms. Wilson’s reaction would have been avoided if she had been tested with a two-step procedure when she first joined the hospital. In any event, because she has a positive reaction, Ms. Wilson should be evaluated for TB disease.

3.5. **Mr. Lee has a cough and other symptoms of TB disease, and he is evaluated with a chest x-ray. However, he is unable to cough up any sputum on his own for the bacteriologic examination.**

**What should be done?**

If a patient cannot cough up a sputum specimen, other techniques can be used to obtain sputum. First, clinicians can try to obtain an induced sputum sample. If they cannot obtain an induced sputum sample, a bronchoscopy or gastric washing may be done.
Case Study Answers, Continued

3.6. Ms. Thompson gave three sputum specimens, which were sent to the laboratory for smear examination and culture. The smear results were reported as 4+, 3+, and 4+.

What do these results tell you about Ms. Thompson’s diagnosis and her infectiousness?

These results show that Ms. Thompson’s sputum specimens contain many acid-fast bacilli. Because the smears are positive, clinicians should suspect that Ms. Thompson has TB disease. They should also consider her infectious. However, it is possible that these acid-fast bacilli are mycobacteria other than tubercle bacilli. Therefore, the diagnosis of TB disease cannot be proven until the culture results are available.

3.7. Mr. Sagoo has symptoms of TB disease and a cavity on his chest x-ray, but all of his sputum smears are negative for acid-fast bacilli.

Does this rule out the diagnosis of pulmonary TB disease?

No.

Why or why not?

*M. tuberculosis* may grow in the cultures even though there were no acid-fast bacilli on the smear. Mr. Sagoo’s symptoms and his abnormal chest x-ray suggest that he does have pulmonary TB disease.

3.8. In the public health clinic, you see a patient, Ms. Sanchez, who complains of weight loss, fever, and a cough of 4 weeks’ duration. When questioned, she reports that she has been treated for TB disease in the past and that she occasionally injects heroin.

What parts of Ms. Sanchez’s medical history lead you to suspect TB disease?

Ms. Sanchez has symptoms of TB disease (weight loss, fever, and a persistent cough). Also, in the past she has been treated for TB disease. We don’t know whether she completed therapy, but until we can prove otherwise, we should assume that she has TB disease again. Her history of injecting illegal drugs (heroin) is another risk factor for TB.

What diagnostic tests should be done?

People who have TB symptoms should be evaluated for TB disease. Because she has symptoms of pulmonary TB disease (coughing), Ms. Sanchez should be given a chest x-ray. In addition, a sputum specimen should be collected for smear and culture, blood for an HIV test, and drug susceptibility testing should be done if the culture is positive for *M. tuberculosis*. 